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Autosomal Dominant Leukodystrophy (ADLD) is a neurodegenerative disorder that affects 
the central nervous system. It is a rare and late onset lethal progressive disorder without any 
effective treatment up to date. Genetically it is characterized by Lamin B1 gene duplication 
or deletion upstream the gene but the mechanisms of how the overexpression of a nuclear 
structural protein leads to such specific symptom as demyelination are still unclear. 
Considering the pivotal role that glial cells as astrocytes and oligodendrocytes and Leukemia 
Inhibitory Factor (LIF) have in the myelination process, this work was intended to analyse the 
morpho-functional aspects of different cell populations, which are engineered cellular 
models overexpressing Lamin B1 and primary cells deriving from ADLD patients. The results 
have, to date, highlighted that the astrocytes may be pivotal in the development of the 
disease. Analysing the cellular ultrastructure, astrocytes overexpressing Lamin B1 show 
several nuclear alterations similar to the ones observed in cells deriving from ADLD patients, 
which, on the contrary are not present in oligodendrocytes overexpressing Lamin B1. In 
addiction astrocytes overexpressing Lamin B1 are not capable to produce LIF and besides the 
receptor (LIF-R) is downregulated, it is downregulated as well as in oligodendrocytes 
overexpressing Lamin B1. In both engineered models, the confirmation that this signalling 
pathway is altered in the cell overexpressing Lamin B1, is given to us by analysing  the 
signalling transduction  pathways downstream LIF/LIF-R. In fact, both PI3K/AKT and 
JAK/STAT3 axes are downregulated but surprisingly with exogenous LIF administration is 
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possible recovered the phenotype. In particular, the toxic effect induced by Lamin B1 
accumulation results in the ability of oligodendrocytes, being less affected, to completely 
recover the phenotype, which instead is only partial for astrocytes. Therefore, this leads us 
to hypothesize that astrocytes, being severely affected by Lamin B1 accumulation, lose their 
role of support for the oligodendrocytes in the myelination process. Finally, inflammation 
and ROS production was also been found in ADLD patients’ cells as alleged in literature in 
relation to the Lamin B1 accumulation and advancement of age. These new discoveries both 
as regards cellular, morphological and functional alterations, and as regards the 
inflammatory process and oxidative stress could pay the way for new avenues of 
investigation in the ADLD disease.  
 
Key words: Lamin B1, ADLD, astrocytes, LIF, cellular signalling  
Abbreviations: 
 ADLD Autosomal Dominant Leukodystrophy 
 CNS Central Nervous System 
 Erk Extracellular signal-regulated kinase 
 GFP Green fluorescent protein 
 GS3K Glycogen synthase kinase 3 
 JAK Janus kinase 
 IF Immunofluorescence 
 LIF Leukemia Inhibitory Factor 
 LIF-R LIF-Receptor 
 LMNB1 Lamin B1 
 MAPK Mitogen-activated protein kinase 
 PNS Peripheral Nervous System 
 PI3K Phosphatidylinositol-3 phosphate kinase 
 STAT3 Signal transducer and activator of transcription protein 3 





1. Hereditary leukodystrophies and Autosomal Dominant 
Leukodystrophy 
 
1.1. Hereditary leukodystrophies 
 
Hereditary leukodystrophies are a heterogeneous group of rare and often progressive 
disorders, presenting with a wide range of symptoms and complications. The pathological 
bases that unite them are alterations of the glial cells or myelin sheaths leading to neuronal 
degeneration affecting the white matter or myelin tracts. Therefore, these diseases can 
occur with different degrees of demyelination at the level of the Central Nervous System 
(CNS) or Peripheral Nervous System (PNS) or both 1. Myelin sheaths, characteristic elements 
of vertebrates, promote the propagation of electrical impulses along the axon of myelin 
fibres in the nervous system. This production is determined by specific cells, such as 
oligodendrocytes, for what concern the CNS, or Schwann cells in the PNS. In the CNS, 
oligodendrocytes are the largest producers of myelin through wrapping of their plasma 
membranes around axons or nerve fibres in a spiral manner. In this way oligodendrocytes 
ensure a rapid conduction of impulses in the nervous system as well as providing metabolic 
support to neurons 2; just as astrocytes, which are equally important both in maintaining 
homeostasis of the CNS and as a supporter of the myelination process 3.  
Numerous molecular mechanisms regulating the specification, differentiation and 
myelination of these cells of the nervous system have been identified, demonstrating that 
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possible failures in the regulation of these molecular processes may result in myelin 
malformation or degeneration resulting in several human diseases as the  hereditary 
leukodystrophies or multiple sclerosis 4. 
The most common example of hereditary leukodystrophy is the X-linked 
adrenoleukodystrophy (X-ALD, OMIM#300100) a genetic disorder that occurs primarily in 
males. It is caused by mutations in ABCD1 gene, encoding for the adrenoleukodystrophy 
protein (ALDP) 5. Since this protein is used for the transport of long chain fatty acids inside 
peroxisomes for their degradation, as a result of the mutation, a lipid accumulation occurs in 
all body tissues 6. The resulting pathological phenotype may include an asymptomatic state, 
adrenergic insufficiency, cerebral demyelination in presence of inflammation and a 
progressive state of spastic paraparesis 7. The prevalence of X-ALD is 1 in 20,000 to 50,000 
individuals worldwide occurring with a similar frequency in all populations. 
Another important example of hereditary leukodystrophy is the Krabbe’s disease 
(OMIM#245200) that is due to a mutation in the GALC gene, which encodes for the 
lysosomal enzyme galactosilceramidase 7. The genetic mutation leads to a decrease of the 
enzyme functionality and a white matter alteration both at the CNS and PNS level, resulting 
in spastic events, delay in development, and irritability. In the United States, Krabbe 
disease affects about 1 in 100,000 people and individuals with late-onset Krabbe 
disease may survive many years after the onset of the disease. 
Finally, to mention another less common leukodystrophy, it must be remembered the 
Pelizaeus-Merzbacher Disease (PMD, OMIM#312080) another inherited condition that 
primarily affects males as in the case of the X-ALD. The prevalence of this disease is 
estimated to be 1 in 200,000 to 500,000 males in the United States. Genetically it exhibits 
mutation of the gene coding for proteolipid protein that is the major component of myelin 
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sheaths. At cellular level, oligodendrocytes, astrocytes, microglia and neurons are affected 
by several mechanisms 8; the cellular alterations may determine, with different processes, 
initial nystagmus, hypotonia, cognitive problems, progressive ataxia and spasticity 7. 
The Autosomal Dominant Leukodystrophy (ADLD, OMIM#169500) belongs to the 
leukodystrophies group and it will be illustrated in the next chapters, focusing on its 





1.2 ADLD: Nomenclature and Epidemiology 
 
Autosomal Dominant Leukodystrophy is a rare, fatal and late onset slowly progressive 
demyelinating disorder, which affects the white matter of the central nervous system. 
It was originally known as "autosomal dominant leukodystrophy mimicking chronic 
progressive multiple sclerosis" and "adult-onset leukodystrophy simulating chronic 
progressive multiple sclerosis" 9 10 . The most known names to date are “Adult-onset 
autosomal dominant Leukodystrophy” or more commonly “Autosomal Dominant 
Leukodystrophy” abbreviated as ADLD. 
The disease presents in the fourth to fifth decades of adulthood without any gender 
differences. Penetrance is not known yet but is assumed to be 100%; also, the prevalence is 
unknown. Published cases include 24 different families with more than 70 affected 
individuals and with different origins: 
 Irish-American11 





 German17  









1.3 ADLD: the genetic basis 
 
ADLD is an inherited disease. The first linkage studies was conduct by Coffeen at all. in 2000 
by discovering that the abnormal gene causing the ADLD disease is localized into 
chromosome 5q31 19. Later, Padiath at al., by analysing the same kindred used by Coffeen 
and another Irish American kindred, were able to identify that this region presents an extra 
copy (duplication) 1, tandemly oriented in a head to-tail manner, of the LAMIN B1 gene 
(LMNB1) on 5q23.2 chromosome 1. Further studies, carried out on 20 ADLD total families, 
have shown that a duplication of 72 kb of LMNB1 is sufficient to define the pathological 
phenotype 20. The LMNB1 gene encodes for the nuclear laminar protein called Lamin B1 1. In 
ADLD patients, a duplication of LMNB1 is associated with an increase of Lamin B1 protein 
levels, confirmed by several analysis of RNA and protein expression conduced in post 
mortem patient’s brain tissue. This would be the genetic classification to identify an ADLD 
patient except that Brussino et al. in 2009 described a new family with a genetic defect in 
5q23 chromosome without copy number mutations 13. Independently to that, when Lamin 
B1 mRNA expression levels were analysed, the expression were significantly increased in 
ADLD patients compared to controls, leading to the conclusion that a cis-acting regulatory 
mutation may have led to the increased mRNA levels 21. As a result from the etiological point 
of view, it can be said that ADLD is caused by chromosomal rearrangements that regardless 
of whether it is duplication of the LMNB1 gene (5q23.2) or deletion upstream of the gene, it 
causes an increase in the expression level of Lamin B1, which is responsible for the ADLD 
















1.4 ADLD: clinical signs 
 
ADLD was described for the first time in 1984 by  Eldridge et al. in a large Irish American 
family 9. Affected members showed progressive and fatal neurological disorders at the 
expense of the white matter in the CNS, without any involvement of neurons, such as 
Purkinje cells 9. 
Subsequently similar phenotypes, deriving from different ethnicities, has been found in a 
Japanese 23, Italian 12, French24 and Swedish family 14. 
Before reaching the genetic cause, the characteristics that united these groups were 
generally due to the phenotypic observation attributable to autonomic dysfunction from 
bladder or bowel  to orthostatic hypotension, temperature dysregulation, and anhidrosis 11 
Figure 1  Genomic region on chromosome 5q23.2 containing the LMNB1 gene. The  blue bar are 
representative for  the genomic duplications in two different ADLD patients showing the centromeric and 
telomeric junctions near  to the LMNB1 gene, the minimal critical region required for ADLD disease (dashed 
line). The red bar indicates the deletion upstream the LMNB1 gene and in black  the location of genes 




21. The primary autonomic symptoms are followed by cerebellar dysfunction (ataxia, 
dysmetria, nystagmus, tremor) and pyramidal defects (spasms and weakening of the 
limbs)4,as well as, in some cases, cognitive, auditory and visual defects were also 
encountered 10 22. 
For a long time, before the use of Magnetic Resonance Imaging (MRI)  or  computerised axial 
tomography, ADLD patients were diagnosed as having chronic progressive multiple sclerosis 
(MS) 11. The use of MRI was the first method which allowed the experts to distinguish ADLD 
patients from MS patients 25, and currently MRI is still one of the first analysis technique 
used for the identification of this rare disease. In ADLD patients compared with MS presents, 
MRI imaging shows widespread and symmetrical degeneration of white matter in the CNS.  
This deterioration starts from the motor cortex to the medulla oblongata and leads to the 
following involvement of the upper and middle cerebellar peduncles 13 19 26.  
Histopathologically, white matter abnormalities in superiomedial portions of the frontal and 
parietal lobes have been described, also some involvement of the corpus callosum, 
cerebellar peduncles and the hemispheres, underlining an important vacuolar demyelination 
processes at the light microscopy observation 19 27 22 . 
Besides this, the ADLD can be distinguished from MS through the study of family history, 
which suggests an autosomal dominant inheritance mechanism 9. Indeed, unlike ADLD 
(highly penetrating, autosomal dominant and adult onset disease), the most hereditary 
leukodystrophies present as autosomal recessive or recessive pathologies related to the X 
chromosome and the age of onset is typically childhood as  for  adrenoleukodystrophy, 
Krabbe’s disease and PMD 1. In addition, other distinctive symptoms that allow to distinguish 
ADLD from MS are: 
 the initial autonomic dysfunction, element never found in MS patients; 
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 the extensive and symmetric demyelination, which in MS is asymmetrical; 
 the absence of an immune response directed against the myelin protein with 
consequent inflammation; 
 neuropathology does not present phenomena of astrogliosis and there is the 
maintenance of oligodendroglia, although in the presence of subtotal demyelination 







Figure 2. (A) Magnetic resonance imagining (MRI) of ADLD patient brain showing intensities symmetrical 
white matter extending from the motor cortex to the medulla oblongata and the involvement of the upper 
and middle cerebellar peduncles, marked by arrows, indicating myelin defect. (B) ADLD patient brain 
showing irregular areas of myelin loss marked by asterisk (*)  respect  areas of normal myelin marked by  
plus sign (+). (C) ADLD brain section  analysed using a myelin stain showing areas of vacuolar demyelination 
marked by asterisks (∗) compared to normal myelin staining indicates with  plus sign (+). 
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2. Lamin B1 alterations 
 
The nuclear lamina is a protein three-dimensional structure of fibrous meshwork of 
intermediate filaments (IFs) that underlie the inner nuclear membrane 28. In mammalian 
cells it is composed by four major types of different lamins: 
 The A-type lamins,  including pre- lamin A, lamin A and C which are alternate splice 
forms of the same gene LMNA, on 1q21 chromosome 29 30. 
 The B-type lamins, comprising lamin B1 and B2, coded by separate LMNB1 and 
LMNB2 genes, on 5q23 and 19q13 chromosomes  31. 
Based on their structural characteristics and their amino acid sequence, lamins are classified 
as intermediate filaments of type V. Like other IFs they are fibrous proteins that join 
together forming filaments presenting central α-helical rod domains and a variable head and 
tail domains. Initially two α-helices wrap around each other in  parallel to form a lamin-lamin 
dimer, the basic filament building block, then these dimers are associated with many others 




















Originally, it was believed that nuclear lamina was a passive structural component of the 
cell, able to provide only integrity to the nucleus. Later, several studies have demonstrated 
that nuclear lamina plays multiple and dynamic functional roles in numerous cellular process 
33 34 , giving structural support to the nucleus and playing dynamic roles in the regulation of 
chromatin, during the transcription, DNA replication and regulating epigenetic 
phenomena35.  
Mutations in genes encoding for nuclear lamina have been described in a large number of 
diseases, most of which are associated with lamin A/C alteration and called “laminopathies”. 
ADLD is the first disease, linked to Lamin B1 mutations, that leads to an enrichment of the 
role played by nuclear lamina and its involvement in nervous system disorders. Although 
Lamin B1 is present in different cell types, its activity is most important during neural 
Figure 3. This image is composed by an image detected by transmission electron micrograph showing the nuclear 
lamina meshwork of nuclear envelope spread from Xenopus oocytes. Scale bar = 1 μm. Copyright Nature Publishing 
group; and by schematic representation of a nuclear lamin assembling where two lamin polypeptides create the 
nuclear lamin dimer through the ability to form two-stranded -helical coiled coils, wrapped around each other, then 
the nuclear lamin dimers associating in a head-to-tail manner form polymers and finally the formation of Filaments. 
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development and for brain functions in adulthood 4. Consequently, modifications that alter 
its expression are attributable to adverse effects for cell survival as described below. An 
important function of Lamin B1 is the regulation of gene expression through the  association 
with specific transcription factors such as sterol response element binding protein 1 
(SREBP1) or the octamer transcription factor (Oct-1) 36. The latter, in particular, is an 
important factor for the regulation of genes involved in response to oxidative stress and co-
localizes with Lamin B1. In mouse model, it was demonstrated that Lamin B1 deficiency 
leads to a dysregulation of Oct-1-dependent genes causing an increase of reactive oxygen 
species (ROS) 36, which are very toxic for the cell, and that cause a harmful and irreversible 
effect on it. In equal measure also, an overexpression of Lamin B1 leads to several 
consequences. Several studies on human (HEK 293) and murine (Ng2a) cell lines, have shown 
that, Lamin B1 overexpression through the increase of the protein level, leads to an increase 
in the nuclear rigidity and this is also found in the nuclei of epithelial fibroblasts of ADLD 
patients 37. 
As well as nuclear structural changes 38, Lamin B1 accumulation in relation to several stress 
conditions was also  linked with senescence 39, as observed in Ataxia telangiectasia (A-T) 
cells, an autosomal-recessive genetic disorder. The oxidative stress, causing Lamin B1 
overexpression, leads to an alterations of the  nuclear shape, and considering the  failure to 
reduce the reactive oxygen species, the cell goes towards an early senescence 39. 
Although Lamin B1 accumulation has been linked to both nuclear structural changes and 
senescence,  its role is still controversial, challenging and tissue- specific 40–43. In ADLD 
disease, despite the genetic causes, the molecular aspects of this pathology are not clear yet 





3. Molecular and cellular mechanisms implicated in the 
myelination process 
 
The mechanisms regulating myelination are still unclear. Myelin is formed by the extension 
of oligodendrocytes cell membranes, which wrap around the axons of neurons in a spiral 
manner. It is composed for the 70–80% by lipid and 20–30% by protein. The most abundant 
proteins are myelin basic protein (MBP) and proteolipid protein (PLP1) which together 
constitute 80–90% of total myelin protein. The remaining part is composed by myelin-
associated glycoprotein (MAG) and myelin oligodendrocyte glycoprotein (MOG) 44 45. 
Myelination process begins during late stages of fetal development and continues into early 
adult life 46. In the CNS of vertebrates, until recently, the saltatory nerve conduction was 
considered the only purpose of myelin 47, on the contrary, currently, it is know that myelin is 
implicated in several cellular function,  by providing metabolic support to neurons 48, 
regulating ion and water homeostasis, and adapting to activity-dependent neuronal signals 
49. 
Oligodendrocyte cells, are certainly the primary cells responsible for myelinating axons 50 , 
but signals deriving from astrocytes and neurons are also essential to promote myelin 
formation and its maintenance during the life 51. 
Astrocytes, in particular, play an important role supporting myelination 3 through the 
secretion of several factors. Among these soluble factors there are: platelet-derived growth 
factor (PDGF), basic fibroblast growth factor (FGF2), insulin-like growth factor 1 (IGF-1), 
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ciliary neurotrophic factor (CNTF), metalloproteinase-1(TIMP-1), and endothelin-1 (ET-1) and 
Leukemia Inhibitory Factor like protein (LIF) 49. 
Leukemia Inhibitory Factor (LIF), compared to these molecules studied in the CNS, arouses 
particular interest for what concern the myelination process and, therefore, it is classified as 
a pro-myelinating factor 46. LIF is a multi-functional cytokine belonging to the interleukin 6 
(IL-6) superfamily. Its name derived from the discovery of this factor able to induce the 
differentiation of murine M1 myeloid leukaemia and macrophage maturation to suppress 
leukaemia proliferation 52. It can regulate several biological processes, through both 
autocrine and paracrine  signalling, including differentiation of leukaemia cell, neuronal 
development, inflammatory response, stem cell self-renewal and cancer progression 53. It is 
extensively studied in neuronal development, because of its influence on neuronal survival 
and differentiation in the peripheral nervous system, its involvement in the induction of the 
switch of neurotransmitter expression in sympathetic neurons and because of its ability to 
induce sensory neurons in response to trauma but especially for the stimulation of the glial 
development 54 . 
LIF binds to its specific receptors with high affinity, the heterodimeric glycoprotein 130 
(gp130)/LIF receptor (LIFR) complex. This specific binding leads to the activation of 3 main 
signal transduction pathways: the Janus kinase/signal transducer and activator of 
transcription protein 3 (JAK/STAT3), phosphatidylinositol-3 phosphate kinase (PI3K/Akt) and 
mitogen-activated protein kinase MAPK/ERK1/2 pathways 55. The activation of these 3 
pathways promote cell growth , proliferation and survival but in particular, this signal 
pathways promote the survival and differentiation of oligodendrocytes delivering  the 





4. LIF signal transduction pathways: JAK/STAT, PI3K/Akt and 
MAPK/ERK signalling. 
 
Upon LIF binding to its specific receptor gp130/LIFR, three main signalling pathways can be 
subsequently activated: JAK/STAT, PI3K/Akt and MAPK/ERK signalling (Figure 4). The 
activation by phosphorylation of each signalling pathway is different for each cell types, but 
they are essential to promote actions in which LIF exerts its effect, such as: change of gene 
expression, cell survival and an anti-apoptotic effect 56. Several studies conducted on 
embryonic stem cell, have demonstrated that JAK/STAT signalling controls genes that 
regulate self-renewal, PI3K/Akt signalling controls genes implicated in cell pro-survival and 
MAPK/ERK signalling controls genes involved in proliferation and self-renewal 57. For what 
concern the regulation of neuronal signalling, one of the most important roles played by LIF 
through these signalling pathways is the development and maturation of glial cells and 
neurons, indeed it can: 
 promote the maturation of astrocytes from astrocytic progenitor cells; 
 facilitate the development of mature oligodendrocytes from OPCs; 
 rescue grey and white matter from damage preventing neuronal and 
oligodendrocyte loss; 
 promote neuroprotection after focal cortical injury upregulating antioxidant 




Even if the molecular mechanisms are not clear yet, several studies have demonstrated that 
if the gp130 receptor is genetically removed from astrocytes, astrocyte cannot survive and 
large areas of demyelination begin to form inducing additionally  a pro inflammatory T cell 
response 58. In addiction during CNS injury, infection and inflammation, it was demonstrated 
that astrocytes operate in neuro-regeneration and re-myelination, increasing the expression 
of LIF and preventing oligodendrocytes apoptosis 59. 
This event, poorly studied yet, underlying the important cross-talk between astrocytes and 
oligodendrocytes, not only in healthy conditions but also in disease, and, considering that 
















Figure 4. LIF signal transduction pathways. Representative image when LIF binds its 
receptor LIF-R and subsequent activation of 3 essential axes: PI3K/AKT, JAK/STAT3 and 
MAPK/ERK1/2 which are implicated in cell proliferation, survival, self-renewal and control 




5. ADLD: where are we now 
 
Considering that demyelination is the primary condition in ADLD, astrocytes and 
oligodendrocytes are the obvious candidate targets to investigate the molecular mechanism 
at the base of the disease, also knowing the interdependence that these cells have in the 
myelination process. 
Histopathologically, the first analysis of ADLD patient brains, showed that oligodendrocytes 
and neurons did not possess any alternations in morphology and in cell number compared 
with astrocytes, that showed an abnormal beading and shortening of their processes 19. In 
other studies, instead, it was observed that the overexpression of Lamin B1 in 
oligodendrocytes, leads to a premature arrest of oligodendrocytes differentiation with a 
reduction of  MBP and PLP1 protein; on the contrary no alterations were observed in 
astrocytes after the overexpression of Lamin B1 60.  Even murine models have not been able 
to clear up this dilemma. Indeed, the most recent model created with the Lamin B1 
overexpression at oligodendrocytes level, was capable of recapitulating the age-dependent 
motor signs, but not the early autonomic cardiovascular dysfunction, primary sign of ADLD 
61. Transgenic mouse models overexpressing LMNB1 in oligodendrocytes were created by 
other two groups 62 63. The group of Heng et al. have suggested that demyelination could be 
due to a lower transcript levels of myelin genes 63. However no changes in myelin gene 
transcripts were found by the group of Rolyan et al., who nevertheless identified alterations 
in the lipid composition 62. To support these data, Yattah et al. were able to identify Lss gene 
encoding for lanosterol synthase, a key enzyme in cholesterol synthesis, whose expression 
was inversely related to Lamin B1 levels and which is critical for the lipid metabolism 64. As 
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latest data, it has been proposed in 2019 by E. Giorgio e al. the use of ASP-siRNA (allele-
specific silencing by RNA interference)  as a therapeutic strategy to target the non-
duplicated allele of the LMNB1 gene with the aim to reduce the high protein expression level 
close to wild-type levels 65. The use of  interfering RNA treatment has abrogated the ADLD-
specific phenotypes in fibroblasts and in two cellular models: neurons reprogrammed from 
patients’ fibroblasts and murine oligodendrocytes overexpressing human LMNB1. However, 
it was not possible to reproduce the same experiment in a mouse model, because the two 
mouse models currently available (Lmnb1BAC and PLP-LMNB1Tg) are not suitable for this 
experiment 63 66. 
This evidence suggests that is difficult both to create an in vivo model and to pinpoint the 
really cell type which suffer for the increased Lamin B1 expression, for these reasons further 
studies are required. Therefore considering the pivotal and complicated role that Lamin B1 
exerts in nuclear structure maintenance 67 , and considering the cellular processes and the 
important role that astrocytes, oligodendrocytes and LIF have in the myelination of CNS 4, 
the understanding of new possible signalling pathways related to the ADLD pathology need 




Aim of the work 
 
It is still a great challenge understanding how the overexpression of a nuclear structural 
protein determines such a specific symptom as demyelination. To date, the data reported in 
the literature are not sufficient to explain the molecular mechanisms that lead to ADLD 
disease therefore the understanding of new cellular and molecular mechanisms is 
mandatory in order to develop a specific therapeutical approach. 
 For this reason, my PhD project aimed to validate a cellular model able to overexpress 
Lamin B1 and to study its effect primarily for what concerns cellular signalling and 
morphological alterations. In particular, we focused on: 
 Creating two ADLD experimental models by overexpressing Lamin B1 in the 
oligodendrocytic cell line MO3.13 and in the astrocytic cell line U87-MG, both cell 
types typically involved in myelination processes.  
  Identifying a possible molecular target implicated in the myelination process. 
 Analysing alterations in signal transduction pathways. 








The following cell lines were used: 
 U87-MG Human glioblastoma astrocytes (HTB-14 ATCC, Old Town Manassas, Virginia, 
US), cultured in EMEM (Corning, New York, US) with 10% FBS and 1% 
Penicillin/Streptomycin (Sigma-Aldrich, Missouri, US). 
 MO3.13 Human Oligodendrocytic cell line (Cedarlane Laboratories, Burlington, Canada), 
cultured in DMEM (Corning, New York, US) supplemented with 10% FBS and 1% 
Penicillin/Streptomycin, without sodium pyruvate. 
 HEK 293Ta (Genecopoeia Inc, US) Lentiviral Packaging cell line derived from human 
embryonic kidney, were cultured in DMEM (Corning, New York, US) with 10% FBS and 1% 
Penicillin/Streptomycin, however, 5% FBS was used during transfection. 
 Primary human dermal fibroblasts isolated from skin biopsies of six ADLD patients 
carrying LMNB1 gene duplication and six healthy donors, obtained from the IRCCS 
Istituto delle Scienze Neurologiche di Bologna, UOC NeuroMet, Italy. Human primary 
fibroblasts were grown in DMEM supplemented with 10% FBS and 1% 
Penicillin/Streptomycin. 
This study was approved by the AUSL Bologna Ethical Committee and informed consents 
were obtained from all participants. 





Lentiviral transduction  
 
In order to produce lentiviruses to overexpress both LMNB1 and green fluorescent protein 
(GFP) for our disease model, as well as, lentiviruses coding only for GFP as control, EX-I3724-
Lv201 vector coding for Homo Sapiens LMNB1 and EX-NEG-Lv201 vector for empty control 
(Genecopoeia Inc, US) were used. 
 
 
Figure 1. Vector used to overexpress Lamin B1 
 
 
According to manufacturer’s protocol, the Lenti-Pac HIV expression packaging kit 
(Genecopoeia Inc., US) was used to transfect HEK293Ta packaging cells.  The transfection 
mix was composed by adding to OptiMEM: 1 g of target vector DNA, 0.57 g of Gag-pol 
vector, 0.28 g VSV-G vector, 6l of PEI (protonation of polyethylenimine) to have a total 
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DNA:PEI ratio of 1:3. 24 hours and 48 hours after incubation, the supernatants containing 
the virus were collected respectively and used for the transduction of U87-MG, MO3.13 and 
fibroblasts cell lines or alternatively stored at -80°C.  
48 hours after transduction, U87-MG, MO3.13 and fibroblasts were selected for 48 hours in 
growth media supplemented with 2 µg/ml of puromycin (Sigma-Aldrich, Missouri, US) for 






In order to test the ability of LIF to rescue the normal phenotype following Lamin B1 
overexpression, U87-MG and MO3.13 cells were treated with 80 ng/ml of Recombinant 
Human Leukemia Inhibitory Factor, LIF (Thermo Fisher Scientific) 48 hours post transduction 
for 48 hours (96 total hours) 68.  
 
 
RNA extraction, Reverse Transcription and Real-time PCR 
 
The extraction of total RNA from samples was made by using RNeasy Mini Kit (Qiagen, 
Hilden, Germany) and the Nanodrop spectrophotometer was used to quantify extracted 
RNA. 1µg of total RNA was reverse transcribed into cDNA using the iScript gDNA Clear cDNA 
Synthesis Kit (Bio-Rad, Hercules, California, US), following the manufacturer’s protocol. 
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mRNA expression levels were evaluated using a TaqMan probe-based real-time PCR system 
(Thermo Fisher Scientific, Waltham, Massachusetts, US). Real-time PCR was performed using 
100 ng of cDNA per well, with the ABI PRISM 7300 real-time PCR machine (Applied 
Biosystems, Life Technologies, Carlsbad, California, US) and GAPDH was used as 
housekeeping gene. Data are presented as fold changes relative to expression levels of 
control samples in accordance with the 2−ΔΔCT formula. Validated gene probes used are as 
follows: LMNB1 Hs.PT.58.40133522, LIF Hs.PT.58.27705899, LIF-R Hs.PT.58.2980475, GAPDH 
Hs.PT.39a.22214836 (IDT, Coralville, Iowa, US). 
 
Protein Extraction and Western Blot 
 
Cells were lysed with T-PER (Thermo Fisher Scientific®) lysis buffer supplemented with Halt 
protease and phosphatase inhibitor cocktails (Thermo Fisher Scientific, Waltham, 
Massachusetts, US). Lysed cells were sonicated in 1 cycle of 15 seconds duration and at a 
power of 40-50% and finally were quantified with the Bradford Protein Assay (Bio-Rad, 
Hercules, California, US). 40 µg of total proteins were separated on Bolt 4-12% 
polyacrylamide-0.1% commercial SDS gels (Thermo Fisher Scientific, Waltham, 
Massachusetts, US) and transferred onto nitrocellulose membrane. Membranes were 
washed with PBS-0.1% Tween-20 (PBST) and non-specific binding sites were blocked with 
blocking buffer (5% w/v non-fat dry milk in PBST) for 1 hour at room temperature and 
incubated with primary antibodies overnight at 4°C. On the basis of manufacturer’s 
protocols, the antibodies used were diluted 1:1000 in either bovine serum albumin (BSA) or 
milk, washed again with PBST and lastly incubated with peroxidase conjugated secondary 
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antibodies (Thermo Fisher Scientific, Waltham, Massachusetts, US) diluted in PBST for 1 hour 
at room temperature. ECL enhanced chemiluminescence reagents (Thermo Fisher Scientific, 
Waltham, Massachusetts, US) were used for the bands detection and the images were 





Cells were fixed in ice-cold 100% methanol (Sigma-Aldrich, Missouri, US) for 15 minutes at -
20°C. After blocking in 1% bovine serum albumin (BSA) for 1hour at room temperature, cells 
were incubated with primary antibody overnight at 4 °C following the manufacturer’s 
instructions.  Lastly, cells were incubated in the dark at room temperature for 1 hour with 
corresponding secondary antibodies, Anti-Mouse IgG F(ab')2 Fragment antibody conjugated 
to Alexa Fluor 488 (Cell Signaling Technology, Leiden, The Netherlands) or Anti-Rabbit IgG 
F(ab′)2 fragment-Cy3 antibody (Sigma-Aldrich). Lastly, nuclei were stained with ProLong Gold 
Antifade reagent with DAPI (Invitrogen, Thermo Fisher Scientific). Slides were then examined 
under a Zeiss Axio-Imager Z1 fluorescent microscope (Carl Zeiss International, Germany). At 






Antibodies used in western blotting and immunofluorescence analysis 
Lamin B1 (10H34L18) Invitrogen, Thermo Fisher Scientific 
LIF (PA5-21122) Invitrogen, Thermo Fisher Scientific 
PI3K p110α (CST 4249) Cell Signaling Technology (Danvers, MA, US) 
PI3K p110γ (CST 5405) Cell Signaling Technology (Danvers, MA, US) 
phospho - Akt (CST 9271) Cell Signaling Technology (Danvers, MA, US) 
Raptor (CST 2280) Cell Signaling Technology (Danvers, MA, US) 
phospho - Stat3 (CST 9134) Cell Signaling Technology (Danvers, MA, US) 
PKCα (PA517551) Invitrogen, Thermo Fisher Scientific 
phospho - GSK3α/β (CST 8566) Cell Signaling Technology (Danvers, MA, US) 
phospho – p44/42 MAPK (CST 4695) Cell Signaling Technology (Danvers, MA, US) 
phospho - Stat4 (71-7900) Invitrogen, Thermo Fisher Scientific 
phospho - NFkB (CST 3033) Cell Signaling Technology (Danvers, MA, US) 




Enzyme‐Linked Solid Phase Immunosorbent (ELISA) Assay 
 
The concentration of human LIF in growth medium of cultured cells was detected using the 
Human LIF ELISA Kit assay (Invitrogen, Thermo Fisher Scientific).48 hours after transduction, 
cells were puromycin-selected for other 48 hours and 2.5 x 105 cells were seeded per well in 
a 12-well plate.  The next day, supernatants were collected and centrifuged for 10 minutes 
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at 6,000 x g. Following the manufacturer’s instructions, a dilution 1:2 was performed for 
each supernatant before assaying in triplicate wells. For each sample (wild type, empty 
vector and LMNB1 overexpressing cells), three supernatants obtained from three separate 
experiments were assayed. To read absorbance at 450nm (primary wavelength) and at 
620nm (reference wavelength) it was used Glomax Discover (Promega, Madison, Wisconsin, 
US). Analysed data are presented as Mean ± Standard Deviation. 
 
Transmission Electron Microscopy (TEM) analysis 
 
U87-MG, MO3.13 cells and primary healthy donors and ADLD patients fibroblasts were fixed 
with 2.5% glutaraldehyde in 0.1M cacodylate buffer, for 2 h at 4°C and then, post fixed in 1% 
OsO4 in 0.1 M cacodylate buffer, for 30 minutes at room temperature. After few washes in 
0.15 M cacodylate buffer, samples were dehydrated through graded acetone solutions and 
embedded in Epoxy resin (Sigma Aldrich, St. Louis, Missouri, US). Sections of 100 nm each 
were collected in nickel grids, counterstained with 3% uranyl acetate and 1% lead citrate and 
observed by Philips CM10 TEM (FEI Company, Eindhoven, The Netherlands), at an 
accelerating voltage of 80 kV. Images were recorded by Megaview III digital camera (FEI 
Company, Eindhoven, The Netherlands). 
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Quantitative analysis of misshaped nuclei 
 
Primary fibroblasts grown on cover glasses and processed for immunofluorescence labelling 
were used for a quantitative analysis of misshaped nuclei compared to regular nuclei 
between healthy donors and ADLD patients. Quantitative analysis was performed on 100 
nuclei of cultured fibroblasts from each patient, at 60X magnification. The number of 
misshaped nuclei was compared to regular nuclei and results were expressed as average 
value (± SD), in percentage, and they were graphically represented for ADLD patients and 
healthy donors. 
 
ROS production assessment 
 
Intracellular reactive oxygen (ROS) species production was tested in primary fibroblasts 
using the cell-permeant probe 2’-7’-dichlorofluorescein (H2DCFDA), a nonfluorescent 
reduced form of fluorescein, which becomes fluorescent upon cleavage by intracellular 
esterases and oxidation by ROS. The fluorescence was monitored with GloMax® Discover 
Microplate Reader Technology using 475 nm (blue) as excitation wavelength and 500-550 
nm emission wavelength. 
The probe was dissolved in DMSO to obtain a 5 mM solution, kept at -20°C and aliquoted in 
amber micro-tubes to protect it from light-induced oxidation, until the preparation of the 
fresh 5µM ready-to-use solution. 4.5 x 105 fibroblasts/sample were washed twice and 
resuspended in 450 µl of PBS. To assess autofluorescence, 150 µl of the sample were used 
and the remaining cells were incubated for 10 minutes at 37°C with 5µM H2DCFDA, in order 
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to load the fluorescent probe. After incubation, 150 µl of fibroblast suspension were left 
untreated to measure basal ROS production while 150 µl were treated with 300 µM H2O2 to 
evaluate the oxidative activity in response to a stimulus. 50 µl of fibroblasts suspension were 
seeded per well in a black 96-well plate. For each triplicate sample, the autofluorescence, 
basal ROS production, and ROS production following H2O2 treatment were analysed. 





Statistical analysis was carried out using GRAPH PAD PRISM 5.0 software (San Diego, CA, US) 
by applying the two-way ANOVA and Sidak post-test. The differences were considered 





In vitro models 
 
1. Astrocytic and oligodendrocytic cell lines 
 
1.1. Evaluation of Lamin B1 overexpression and localization. 
 
In order to study the effect of Lamin B1 overexpression, astrocytes U87-MG and 
oligodendrocytes MO3.13 cell lines were transiently transduced with lentiviral infection. 
After puromycin selection, cells were tested for Lamin B1 expression both at mRNA and 
protein levels and compared to wild type (WT) and cells transduced with an empty vector 
coding only for green fluorescent protein (GFP). In addition, Lamin B1 nuclear localization 







Figure 1  Evaluation of Lamin B1 overexpression  in U87-MG and MO3.13  through qRT-PCR, Western blot  analysis and 




After 96-hour transduction, both overexpressed cell lines (ovLMNB1) show high levels of 
Lamin B1 mRNA and protein compared to WT and GFP (Fig. 1A, 1B, 1D, and 1E). The 
expression levels of Lamin B1 are greater in U87-MG (1A-1B) than in MO3.13 cells (1D-1E). 
Also the IF analysis (1C-1F) confirmed an increased immunoreactivity in transduced cells 
(ovLMNB1) compared to controls WT and GFP and this confirmed the different levels of 
overexpression reached in the two cell line models: U87-MG astrocytic cell line being the 
one showing higher levels of Lamin B1 overexpression. Additionally, IF images show that 
Lamin B1 is localized in the nucleus, particularly in the nuclear lamina and nucleoplasm, both 
in transduced U87-MG and in MO3.13 with evident alterations in the nuclear shape of U87-
MG cells compared to MO3.13 following Lamin B1 accumulation. GAPDH and β-tubulin were 
used respectively as housekeeping gene and loading control. For the immunofluorescence, 




1.2. Lamin B1 overexpression affects nuclear morphology in U87-MG cells 
The nuclear morphology was evaluated by transmission electron microscopy (TEM) (Fig. 2) 
and nuclear shape was examined both in U87-MG and in MO3.13 cell lines. 
 
TEM analysis in U87-MG WT and GFP cells shows normal polygonal shape with round nuclei 
and well-preserved chromatin and nucleoli and a regular nuclear envelope composed by two 
membrane bilayers (Fig. 2A and 2B). In U87-MG cells overexpressing Lamin B1 (ovLMNB1) 
on the contrary a round-shaped morphology with misshaped and folded nuclei was observed 
(Fig. 2C) and at higher magnification, the nuclear envelope appears to be composed of 
stacked membrane layers surrounding the chromatin which is highly condensed in few 
masses (Fig. 2D). 
Figure 2 TEM analysis of U87-MG: (A) Wild type U87-MG cells  observed at bar: 5 m; (B) GFP transduced U87 cells at bar: 
5000 nm; (C) U87-MG cells overexpressing Lamin B1 at bar: 2000 nm and (D) the nuclear envelope observed  at bar: 1000 
nm; TEM analysis of MO3.13 cells: (E) Wild type MO3.13 cells and (F) GFP transduced MO3.13 at bar: 5000nm;(G) MO3.13 
cells overexpressing Lamin B1 at bar: 5 m. (H) nuclear envelope(arrow), mitochondria (*) and regular endoplasmic 




MO3.13 WT and GFP cells show polygonal shape morphology, well-preserved nucleus, 
nucleoli and a normal nuclear envelope (Fig. 2E and 2F) and also MO3.13 overexpressing 
Lamin B1 shows well-preserved morphology, with regular shaped nuclei and nucleoli 
(Fig. 2G), and regular chromatin (Fig. 2H). 
 
 
1.3. The overexpression of Lamin B1 causes both LIF and LIF-R reduction 
Given the pivotal role that Leukemia Inhibitory Factor (LIF) has in the myelination and in the 
crosstalk between astrocytes and oligodendrocytes, it was examined the expression levels of 
LIF and its receptor LIF-R in U87-MG cells, the cells that produce LIF, and only the expression 
of LIF-R in MO3.13 cells, after Lamin B1 overexpression (Fig. 3A-B). Cells were tested after 48 









Figure 3 (A-B) qRT-PCR analysis shows that Lamin B1 overexpression reduces both LIF and LIF-R m RNA level in 
U87-MG (A) and LIF-R mRNA level in MO3.13 (B). 
***p<0.001 
** <p0.0.1 
* p <0.05 
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Real-time PCR analysis shows that in U87-MG cells overexpressing Lamin B1 there is a 
reduction of both LIF and LIF-R at mRNA levels compared to WT and GFP cells (Fig. 3A). In 
addition, also MO3.13 cells following Lamin B1 overexpression shows an important 
reduction of LIF-R expression (Fig. B). To confirm that LIF production was reduced in U87-MG 







First, it was evaluated LIF production in WT, GFP and ovLMNB1 by Western blot, confirming 
the effective decrease in LIF expression following Lamin B1 overexpression (Fig. 3C). Next, 
we analysed LIF concentration in the supernatants of WT, GFP and ovLMNB1 by ELISA test 
demonstrating that LIF concentration was also in this case  reduced in the supernatants of 
Lamin B1 overexpressing cells (Fig. 3D). This data suggests that the decrease seen at the 
D C 
Figure3 (C-D) LIF protein expression in U87-MG analysed by western blot (C) and LIF concentration 
supernatants in U87-MG tested by ELISA test. 
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mRNA level corresponds to an actual decrease in LIF production at the protein level and in 
its release in the culture medium. 
All the analyses are representative of three independent experiments, with *p<0.05; 
**p<0.01 and ***p<0.001 vs corresponding GFP sample. GAPDH and β-tubulin were used as 





1.4. Lamin B1 accumulation affects the LIF-R downstream pathways 
To verify if the signalling cascades are active in Lamin B1 overexpressing cells when LIF binds 
to its receptor LIF-R, three principal pathways have been investigated: PI3K/AKT, Jak/STAT3 
and ERK1/2 pathways. In particular, it was evaluated the expression and the phosphorylation 
of some fundamental molecules downstream LIF- signalling pathway in both U87-MG and 
MO3.13 cells 96 hours after transduction. Lamin B1 transduced cells (ovLMNB1) were 
compared to WT and GFP sample and β-tubulin was used as loading control for the 























Fig. 4A shows that Lamin B1 overexpression in U87-MG cells (ovLMNB1) leads to a down-
regulation of the molecules belonging to the PI3K/AKT pathway. The amount of PI3K p110α 
and γ subunits were both reduced. Also, Akt phosphorylation and the expression of Raptor, 
the two components of mTORC1 complex, were reduced. However, the levels of 
phosphorylated GSK3 increased in parallel by the increase of PKCα expression. On the 
contrary, Stat3 pathway was downregulated, as confirmed by observing the reduction of 
Figure 4 Effect of Lamin B1 accumulation on the expression and phosphorylation of LIF-R 
downstream signaling molecules. Analysis conducted by Western blot  (A): representative panel 




Stat3 phosphorylation compared to WT and GFP. Finally, the phosphorylation levels of 
p44/42 MAPK (Erk1/2) were not affected by Lamin B1 overexpression. 
For what concerns MO3.13 cells, Lamin B1 overexpression also caused a reduction in PI3K 
activity as it can be seen through the reduction in PI3K p110α and γ expression, Akt 
phosphorylation and Raptor expression. Stat3 signalling was also downregulated but no 
alterations were observed in GSK3 phosphorylation, PKCα expression and Erk1/2 
phosphorylation (Fig. 4B). 
Western blot analyses are representative of three independent experiments. 
 
 
1.5. Evaluation of LIF exogenous administration on the downregulated 
signalling pathways 
In order to understand if LIF exogenous administration was able to revert the downregulated 
pathways downstream LIF-R after Lamin B1 overexpression, 48 hours after transduction and 
puromycin selection, U87-MG and MO3.13 cells were treated with LIF 80ng/ml for 48 hours. 
Then a Western blot analysis was performed to verify the activation of the downstream 
signalling pathways that in Lamin B1 overexpressing cells were altered. The expression or 
phosphorylation of the denoted molecules were analysed by using β-tubulin as loading 
control and comparing both U87-MG and MO3.13 overexpressing Lamin B1 with the 










Fig. 5A shows that in U87-MG cells, the administration of LIF to Lamin B1 overexpressing 
cells caused an increase of PI3K p110α and γ, Raptor expression and Akt phosphorylation. At 
the same time, it caused a reduction of PKCα expression and GSK3 phosphorylation but no 
effect was observed on Stat3 phosphorylation, which was lower in Lamin B1 overexpressing 
cells compared to WT and GFP cells also after LIF treatment. 
Figure 5 Effects of exogenous administration of on downregulated signaling pathways. Cells were transduced, 
puromycin-selected and either left in growth medium (-) or treated with LIF 80 ng/ml (+) for 48 hours. Panel (A)   




For what concerns MO3.13 cells considering that they do not secrete LIF, it was tested also 
in this case if the stimulation with LIF could counteract the effects of Lamin B1 
overexpression on the signalling pathways downstream LIF-R that are downregulated. 
Surprisingly in this case in Lamin B1 overexpressing cells LIF administration promotes not 
only an increase of PI3K p110α and γ, Raptor expression, and Akt phosphorylation, but also 
in Stat3 phosphorylation (Fig. 5B). These results are representative of three independent 
experiments, which demonstrated that exogenous administration of LIF on U87-MG could 
partially revert the effect of Lamin B1 overexpression on proteins belonging to the PI3K 
pathway but not reactivate Stat3 signalling. On the contrary, LIF administration on MO3.13 
cells could reverse almost completely the effects of Lamin B1 overexpression that were 
associated to a reduction in LIF-R expression as is possible to see the increase of PI3K 




Ex vivo model 
 
2. Primary dermal fibroblasts of ADLD patients and controls 
2.1.   Lamin B1 duplication alters the nuclear structure of primary dermal 
fibroblasts 
In primary dermal fibroblasts obtained from ADLD patients and healthy donors it was 
investigated firstly the expression of Lamin B1 at mRNA and protein levels and secondly their 


















Figure 6 (A-B-C-D) Dermal primary fibroblasts from ADLD patients (ADLDs) and healthy donors (CTRLs) 
evaluated for Lamin B1 expression by qRT-PCR, data are expressed in percentage with ** p<0.01 vs control 
group (A). (B): Western blot evaluating Lamin B1 expression in healthy donors and ADLD patients. (C): 
Representative TEM analysis of dermal primary fibroblasts derived from healthy donors (CTRL) (bar: 5000nm) 
and ADLD patients (ADLD) (bar: 5 m). (D): Quantitative analysis representing the number of misshaped nuclei 
compared to the number of regular nuclei observed in dermal primary fibroblasts from controls (n=6) and ADLD 






Fig. 6A shows average mRNA expression levels for Lamin B1 in 6 ADLD patients and 6 healthy 
donors. Generally, fibroblasts from ADLD patients show elevated level of Lamin B1 mRNA 
expression compared to healthy donors but with high variability between samples of 
different patients. In fact, by observing the Western blot analysis (Fig. 6B) it is possible to 
notice that although ADLDs patients have a greater quantity of protein than the CTRLs, 
between them there is an evident variability. Anyway, analysing the ultrastructure by TEM, 
ADLD patients show more irregular and misshaped nuclei compared to CTRLs as shown in 
the Fig. 6C representative image of 6 primary dermal fibroblasts deriving from ADLD patients 
and 6 healthy donors analysed. Fig. 6D shows a quantitative analysis of the number of 
regular nuclei compared to misshaped nuclei observed in 6 control and 6 ADLD primary 
dermal fibroblasts. It displays the presence of 48.03% of misshaped nuclei in ADLD patients 
compared to 28.6% in healthy donors. Data are expressed in percentage with *p<0.05.   
In order to verify whether the observations perceived in the primary cultures could be 
reproducible and related to the engineered model, dermal fibroblasts from one healthy 
donor were transduced with an empty vector (GFP) and a vector coding for the Lamin B1 
(ovLMNB1). Lamin B1 expression was evaluated by real-time PCR and Western blot analysis. 
GAPDH and β-tubulin were used as loading control and both real-time PCR and Western blot 
















Following the assessment of Lamin B1 overexpression by real-time PCR and western blot, 
nuclear morphology was observed by TEM analysis (Fig. 6G-H-I) revealing that fibroblasts 
overexpressing Lamin B1 (Fig. 6I) showed misshaped and irregular nuclei respect to GFP (Fig. 
6H) and control dermal fibroblast (Fig. 6G). On the contrary, the nuclear envelope of dermal 
fibroblasts overexpressing Lamin B1 did not show any stacked lamellar membranes. 
 
  
Figure6 (G-H-I) Ultrastructure of wild type, and empty vector and Lamin B1- transduced fibroblasts evaluated 
by TEM. Representative TEM images of (WT) and (GFP) observed at bar: 5000 nm and 1 m, respectively; 
fibroblasts overexpressing Lamin B1 (ovLMNB1) observed at bar: 5000 nm. 
Figure 6 (E-F) Primary Dermal fibroblasts cultured from one healthy donor transduced with Lamin B1. (E): 





2.2. Lamin B1 accumulation cause phosphorylation of inflammation 
mediators 
Considering that fibroblasts are involved in chronic inflammation, it was controlled whether 
sample from ADLD patients and healthy donors differ in the activation of inflammation 
mediators. For this reason, following transduction of primary dermal fibroblasts from one 
healthy donor with empty vector GFP and Lamin B1 coding vector, , it was evaluated the 
phosphorylation level of NF-kB and STAT4 and compared to WT cells (Fig 7A). Then the 
correlation between Lamin B1 accumulation and NF-kB and STAT4 phosphorylation was also 
















Figure7 (A-B) Lamin B1 overexpression and inflammation mediators. Primary dermal 
fibroblasts from one healthy donor, transduced with empty vector (GFP) and Lamin B1 
(ovLMNB1) evaluated for NF-kB and STAT4 phosphorylation and compared to wild type 
cells (WT) (A). (B): Representative western blot showing NF-kB and STAT4 




Fig. 7A shows that following Lamin B1 overexpression, transduced fibroblasts (ovLMNB1) 
have higher levels of NF-kB S536 and STAT4 Y693 phosphorylation compared to GFP and WT 
sample. In the same way, Fig. 7B shows that the amount of phosphorylated NF-kB and Stat4 
was higher in patients’ fibroblasts compared to controls. Analysing statistically the 
densitometry values of the Western blot bands, significant difference in the phosphorylation 
levels between the two groups were compared (Fig. 7C) suggesting that ADLD patients 







In the Western blot analysis, β-tubulin was used as loading control (A and B). The 
quantitative analysis (C) was performed on 6 ADLD patients (ADLDs) and 6 healthy donors 
(CTRLs), and data are expressed as average ± SD, ** indicates p<0.01 vs control group. 
  
Figure 7 (C) Quantitative analysis of Lamin B1 expression, NF-kB and STAT4 




2.3. In response to H2O2 treatment ADLD patients produce more ROS 
compared to healthy donors 
 
Finally, it was evaluated another phenomena related to Lamin B1 expression, namely the 
production of reactive oxygen species (ROS) in response to H2O2 treatment. In order to 
determine if fibroblasts from ADLD patients and healthy donors are more responsive to 
oxidative stress, it was analysed the intracellular ROS production after 7 hours of H2O2 















This graph shows the ratio between H2O2 induced and basal ROS production during the time 
course. After 45 minutes of stimulation, the production of ROS is higher in patients’ 
fibroblasts compared to controls, although there is an increase in both (Fig. 8). The 
Figure 8 Fibroblasts’ ROS production in response to H2O2 treatment evaluated in 6 healthy donors (CTRLs) 



























  * p<0.05 
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difference between the mean values was statistically significant in the interval between 45 
and 210 minutes after treatment, being highly significant between 60 and 135 minutes. The 
graph is the mean of three different experiments and the significance expressed with ** 






Autosomal Dominant Leukodystrophy is a rare disease where a duplication of a Lamin B1 
gene leads to the demyelination of the central nervous system in an unknown way such that 
no effective therapies exist to date.  
Considering the pivotal role that astrocytes and oligodendrocytes have in the myelination 
process this work aimed to highlight in detail what happens following Lamin B1 
overexpression in both cell types.  
For this reason, after infecting two cell lines U87-MG (astrocytes) and MO3.13 
(oligodendrocytes) with a lentiviral vector coding for Lamin B1, the first data were quite 
surprising. In fact, after only 96 hours of infection, the two cell lines showed their first 
different characteristics. At the molecular and protein level astrocytes were more affected 
by Lamin B1 accumulation than oligodendrocytes. Although oligodendrocytes also showed a 
good amount of Lamin B1 both at molecular and protein level, the levels of the expression 
were not comparable to those of astrocytes. In fact, astrocytes showed Lamin B1 expression 
level at least 40 times greater than MO3.13 expression level (Fig.1). The subsequent 
morphological analysis of the two cell lines confirmed what was seen in previous analyses, 
showing that although the two infected cell lines showed clear morphological alterations 
compared to the respective wild type and empty control vector, again U87-MG presented 
more massive alterations of the nuclear shape respect MO3.13 cells. 
These completely new and unexpected results have paved the way for a new way of 
investigation in order to try to understand what was "blocked" in the communication 
between these two cell lines such as to cause a demyelination. So, after an accurate study 
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about cell pathways that promote myelin production, it was decided to analyse a key factor 
that drives these two cells to produce myelin, namely LIF. 
LIF is produced by astrocytes and other than supporting their survival, it favours the 
maturation of oligodendrocytes making them capable of producing the proteins necessary 
for myelin 46.  
What was found in our engineered model is that in astrocytes an accumulation of Lamin B1 
induces a reduction in LIF and in LIF-R at molecular level causing a decrease in LIF production 
and its cellular release. Moreover, oligodendrocytes, which cannot physiologically product 
LIF, showed a reduction in LIF-R expression.  
Accordingly, the signalling pathways downstream LIF-R were investigated in both cells lines 
overexpressing Lamin B1, confirming that JAK-STAT3 and PI3K/AKT axes are downregulated, 
while MAPK/ERK axis is not affected. These results may be explained by the fact that the first 
two pathways have a direct connection to LIF axis while MAPK/ERK pathway is connected to 
many other mediators. Additionally, it is very interesting to observe that in U87-MG cells 
overexpressing Lamin B1 GSK3 is more phosphorylated in combination with the increase of 
PKCα expression, suggesting a possible involvement of this protein in the GSK3 
phosphorylation. In MO3.13 cells overexpressing Lamin B1 no variation in GSK3 
phosphorylation was observed.  Therefore, to confirm that the downregulation of the 
pathways implicated in cell survival were actually due to the overexpression of Lamin B1, 
which somehow blocks both LIF production and its receptor expression, we investigated 
whether exogenous LIF administration could recover the activation of the signalling 
pathways downstream LIF-R. It is important to highlight that also these experiments have 
shown differences between the two cell lines. In particular, the administration of LIF 
promotes a phenotype rescue for what concern the protein expression of PI3K p110 α and γ, 
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Raptor and Akt phosphorylation in both U87-MG and MO3.13 cells overexpressing Lamin B1. 
Instead, GSK3 phosphorylation and PKCα expression are reduced only in U87-MG cells 
overexpressing Lamin B1. Probably the treatment induces a reduction of PKCα expression, 
which consecutively reduces the phosphorylation of GSK3. Therefore, the re-activation both 
of PI3K axis and PKCα/ GSK3 may be involved in promoting cell survival.  Moreover, LIF 
administration promotes the STAT3 phosphorylation, but only in MO3.13 cells 
overexpressing Lamin B1. This evidence underlies that it is possible to restore the activation 
of wild type pathways only in oligodendrocytes, using exogenous administration of LIF. This 
difference may be due to the fact that oligodendrocytes are less affected morphologically by 
Lamin B1 accumulation than astrocytes, resulting in their ability to take advance by LIF 
administration and bypass the downregulated receptor. In astrocytes, in which Lamin B1 
accumulation causes the reduction of both LIF and LIF-R expression, LIF administration can 
only partially restore the signalling downstream LIF-R. In fact, STAT3 phosphorylation cannot 
be re-established highlighting that Lamin B1 overexpression drastically affects astrocytic 
function reducing the essential support for oligodendrocytes during the myelination process.  
This is the first time that the identification of cellular signalling and morphological alterations 
in astrocytes has been linked to the ADLD disease. In fact, until now, their role in the disease 
has only been presumed but never investigated. 
Additionally, also primary dermal fibroblasts derived from ADLD patients and fibroblasts 
transduced to overexpress Lamin B1 have shown the ultrastructural nuclear alterations 
similar to those described in the engineer model, such as misshaped and folded nuclei, 
although with less marked evidence. Moreover, in order to add another piece of information 
to this intriguing rare disease we considered that LIF other than promoting astrocytes 
maturation, activation, and oligodendrocytes differentiation,  is  also considered a potential 
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therapeutic drug for Multiple sclerosis (MS) 69 and  neuroinflammatory lesions 70. Therefore, 
it was investigated the role of inflammation in ADLD primary dermal fibroblasts observing 
that ADLD primary fibroblasts have an increase in the phosphorylation of NF-kB and STAT4, 
two important inflammation mediators.  
Finally, considering that oxidative stress has been linked to Lamin B1 accumulation 71 and 
age dependent alterations, it was also investigated the ROS production in response to H2O2 
treatment comparing ADLD primary fibroblasts with the healthy donors, highlighting that 
ADLD primary fibroblasts produce more ROS than healthy donors .  
Surely all these evidences are part of a vast series of evidences destined to intertwine and 
that is why further studies need to be carried out. However, highlighting that astrocyte 
dysfunction could represent the foundation of the disease opens the way to new possible 
















Conclusions and Future perspectives  
 
As previously mentioned, this is the first time that morphological and cellular signalling 
alterations in astrocytes have been linked to the ADLD disease.  
From the morphological point of view, our results have demonstrated that astrocytes cell 
line overexpressing Lamin B1, show severe ultrastructural nuclear alterations, such as 
misshaped and folded nuclei, like in ADLD patients’ primary dermal fibroblasts, while the 
same alterations are not present in the oligodendrocytes cell line overexpressing Lamin B1.  
This suggests that it is possible those different cellular types respond in different ways to the 
overexpression of Lamin B1 and that the accumulation of Lamin B1 in astrocytes might be 
pivotal in determining oligodendrocytes dysfunction via cellular signalling mechanisms. 
Indeed, our results have demonstrated that the communication between astrocytes and 
oligodendrocytes might be altered due to the reduction of LIF release and LIF-R 
downregulation, which are critical elements in the myelination process  46. In addition, while 
considering the intrinsic model limitations in the investigation of the role of inflammation 
and oxidative stress in ADLD primary dermal fibroblasts, our results have highlighted an 
increase in both in ADLD patients’ cells. These data suggest a possible correlation  between 
lipid alterations, inflammation and stress age-related processes 72, which could be at the 
base of a negative loop mechanisms that leads to  the progression of ADLD phenotype. 
For all these reasons, future studies may be directed primarily towards the preparation of 
co-cultures of immortalized astrocytes and oligodendrocyte precursor cells (OPC), in order to 
better understand if the signalling and morphological alterations highlighted in the 
immortalized cell lines, can be confirmed in more physiological conditions. Co-culture might 
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be set up by inducing Lamin B1 overexpression in OPCs and putting them in culture with 
mature astrocytes, to determine OPCs’ ability to differentiate and maturate in response to 
LIF secreted by astrocytes. The expression of the proteins MBP, PLP, MOG required for 
myelin winding could be evaluated. At the same time the complementary experiment could 
be performed, therefore inducing Lamin B1 overexpression in astrocytes and testing their 
ability to induce OPCs differentiation. Moreover, using advanced 3D imaging techniques, a 
co-culture of astrocytes, oligodendrocytes and neurons could be created in order to observe 
the effective myelination/demyelination process directly on the axons, following the 
overexpression of Lamin B1 in both astrocytes and oligodendrocytes or in one cell type at 
the time. These aspects will be essential for the confirmation of the proposed pathological 
mechanisms.  
Then, considering the correlation between morphological alteration and Lamin B1 
accumulation, and the aberrant expression of lipids evident in various neurological disorders 
73, the alteration of lipid signalling pathways might represent an important event underlying 
the disease phenotype. For these reasons and considering that lipids play active roles in 
myelination process, one might investigate the possible alteration of lipid pathways and 
whereas phosphoinositide dependent phospholipases (PI-PLCs) may be altered in the 
pathological phenotype. Indeed these molecules are very abundant in the brain (especially 
the isoforms PI-PLCβ1, PI-PLCɣ1 and PI-PLCβ4) and can be involved in several lipid signalling 
pathway alterations 74  . 
Finally, thanks to the collaboration between the Cellular Signalling Laboratory and the 
Korean Brain Research Institute (KBRI), iPSCs (induced pluripotent stem cells) from ADLD 
primary fibroblasts could be induced to differentiate towards a glial phenotype in order to 
study the molecular and morphological changes on patients’ primary cells.  
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In conclusion, if the results of our in vitro model, which highlight for the first time the 
astrocyte as a determinant player in establishing ADLD phenotype, will be reproducible in 
the future experiments mentioned above, undoubtedly it will be a new starting point for 
future investigations. In fact, it will be possible to create new animal models with the 
overexpression of Lamin B1 in astrocytes, thus abandoning the unsuccessful previous 
models. Moreover, the identification of signal transduction pathways alterations that 
regulate the myelination process of glial cells, will help to identify the underlying 
mechanisms that lead to the onset of the pathological phenotype and to discover molecular 
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